Skip to content

A clinical trial to study the effecs of two drugs, Unani Formulation and Tacrolimus 0.03 Percentage Ointment in children with Pityriyasis Alba.

COMPARATIVE CLINICAL STUDY OF TOPICAL UNANI FORMULATION VS TACROLIMUS 0.03 PERCENTAGE OINTMENT IN BAHAQ ABYAD (PITYRIASIS ALBA) IN CHILDREN: A RANDOMIZED CLINICAL STUDY - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/12/098402
Enrollment
78
Registered
2025-12-03
Start date
Unknown
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L819- Disorder of pigmentation, unspecified Health Condition 2: L305- Pityriasis alba

Interventions

Intervention1: Unani Formulation: The patients will be given Topical Unani Formulation twice a day locally for 60 days. Control Intervention1: Tacrolimus 0.03% 0intment: The patients will be given Tac

Sponsors

Khursheed Alam
Lead Sponsor
Dr Md Sohail
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: Patients in the age group of 3 to 16 years of both genders. Clinically diagnosed case of Bahaq Abyad or Pityriasis Alba. Patients guardian or parents willing to sign the informed consent form and follow the study protocol.

Exclusion criteria

Exclusion criteria: Patient with coexistence of other dermatoses like atopic dermatitis. Use of any medication that could interfere with cellular immunity during past 4 weeks Use of any topical agent within 3 days and 7 days for systemic medication before entry in study.

Design outcomes

Primary

MeasureTime frame
Likert Scale for Hypopigmentation. Pruritus and Scaling.Timepoint: At Baseline 15th days 30th days 45th days 60th days

Secondary

MeasureTime frame
DLQI (Dermatology Life Quality Index)Timepoint: At Baseline 60th days

Countries

India

Contacts

Public ContactFarheen Fatima

State Unani Medical College and Hospital

dr.khursheedmd@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026